Evaluation of prognostic factors in male breast cancer
We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There were 5 (12%) T1tumours, 23 (56%) T2tumours and 13 (32%) T3/T4tumours. They were mostly (95%) infiltrating ductal carcinom...
Gespeichert in:
Veröffentlicht in: | Breast (Edinburgh) 2001-04, Vol.10 (2), p.166-175 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There were 5 (12%) T1tumours, 23 (56%) T2tumours and 13 (32%) T3/T4tumours. They were mostly (95%) infiltrating ductal carcinomas; 97% were grade 2 or 3. Axillary lymph node involvement was found in 69%. Estimated 5-year survival rates were 67% and 58% for overall and relapse free survival respectively. Favourable prognosis was associated with age below 50y, clinical stage I and II, small tumour size (T1, T2), low tumour grade and absence of nodal involvement or distant metastases; nodal status and grade were independent factors for relapse free survival in multivariate analysis. In 18 cases, an immunohistochemical study showed some degree of tumour antigen reaction for ER in 89% of cases, PR in 61%, pS2 in 44%, CathD in 72%, p53 in 56%, c-erbB-2 in 50%, Ki67 and PCNA in 100% and bcl-2 in 78%. There were significant associations between several of these factors but none influenced survival. Despite the high incidence of staining of ER, our data do not support the concept of an endocrine pathway that could be usefully antagonized with antioestrogens for therapeutic benefit, as in women. |
---|---|
ISSN: | 0960-9776 1532-3080 |
DOI: | 10.1054/brst.2000.0223 |